Results 31 to 40 of about 1,282 (161)

Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review

Antibiotics, 2020
Three patients with multi-year histories of relapsing and remitting Lyme disease and associated co-infections despite extended antibiotic therapy were each given double-dose dapsone combination therapy (DDD CT) for a total of 7–8 weeks. At the completion
Richard I. Horowitz, Phyllis R. Freeman
doaj   +1 more source

Infectious mononucleosis-like PTLD [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018
Post-transplant lymphoproliferative disorders (PTLDs) are serious, life-threatening complications of transplantation which represent a heterogeneous group of lymphoproliferative diseases and show a spectrum of clinical, morphologic, and molecular genetic features ranging from reactive polyclonal lesions to frank lymphomas. Infectious mononucleosis (IM)-
openaire   +2 more sources

Mutations in JAK/STAT and NOTCH1 Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders

Frontiers in Oncology, 2022
Post-transplant lymphoproliferative disorders (PTLD) are diseases occurring in immunocompromised patients after hematopoietic stem cell transplantation (HCT) or solid organ transplantation (SOT).
Alexandra Butzmann, Alexandra Butzmann, Kaushik Sridhar, Diwash Jangam, Hanbing Song, Amol Singh, Jyoti Kumar, Karen M. Chisholm, Benjamin Pinsky, Franklin Huang, Robert S. Ohgami   +10 more
doaj   +1 more source

Association of small fiber neuropathy and post treatment Lyme disease syndrome.

PLoS ONE, 2019
ObjectivesTo examine whether post-treatment Lyme disease syndrome (PTLDS) defined by fatigue, cognitive complaints and widespread pain following the treatment of Lyme disease is associated with small fiber neuropathy (SFN) manifesting as autonomic and ...
Peter Novak, Donna Felsenstein, Charlotte Mao, Nadlyne R Octavien, Nevena Zubcevik   +4 more
doaj   +1 more source

The HUMTICK study: protocol for a prospective cohort study on post-treatment Lyme disease syndrome and the disease and cost burden of Lyme borreliosis in Belgium

Archives of Public Health, 2017
Background In Belgium, different routine surveillance systems are in place to follow-up Lyme borreliosis trends. However, accurate data on the disease and monetary burden for the different clinical manifestations are lacking.
Laurence Geebelen, Tinne Lernout, Benoît Kabamba-Mukadi, Veroniek Saegeman, Hein Sprong, Steven Van Gucht, Philippe Beutels, Niko Speybroeck, Katrien Tersago   +8 more
doaj   +1 more source

Lyme borreliosis in Belgium: a cost-of-illness analysis

BMC Public Health, 2022
Background Lyme borreliosis (LB) is the most common tick-borne disease in Europe and North America, yet its economic burden remains largely unknown. This study aimed to estimate the economic cost associated with the different clinical manifestations of ...
Laurence Geebelen, Brecht Devleesschauwer, Tinne Lernout, Katrien Tersago, Yves Parmentier, Herman Van Oyen, Niko Speybroeck, Philippe Beutels   +7 more
doaj   +1 more source

Neuroborreliosis and Post-Treatment Lyme Disease Syndrome: Focus on Children

Life, 2023
Neuroborreliosis is a form of Lyme Borreliosis (LB) that affects various structures of the central and peripheral nervous system. Although most cases of LB can be cured with a course of antibiotics, some children can present prolonged symptoms, which may
Agnieszka Myszkowska-Torz, Magdalena Frydrychowicz, Mateusz Tomaszewski, Magdalena Figlerowicz, Anna Mania, Katarzyna Mazur-Melewska   +5 more
doaj   +1 more source

A Unique “Composite” PTLD with Diffuse Large B-Cell and T/Anaplastic Large Cell Lymphoma Components Occurring 17 Years after Transplant

Case Reports in Hematology, 2013
Posttransplant lymphoproliferative disorder (PTLD) comprises a spectrum ranging from polyclonal hyperplasia to aggressive monoclonal lymphomas. The majority of PTLDs are of B-cell origin while T-cell PTLDs and Hodgkin lymphoma-like PTLDs are uncommon ...
Kristin La Fortune, Dahua Zhang, Gordana Raca, Erik A. Ranheim   +3 more
doaj   +1 more source

Treatment of PTLD with Rituximab or Chemotherapy [PDF]

American Journal of Transplantation, 2006
Information regarding treatment of post-transplant lymphoproliferative disease (PTLD) beyond reduction in immunosuppression (RI) is limited. We retrospectively evaluated patients receiving rituximab and/or chemotherapy for PTLD for response, time to treatment failure (TTF) and overall survival (OS). Thirty-five patients met inclusion criteria.
R L, Elstrom, C, Andreadis, N A, Aqui, V N, Ahya, R D, Bloom, S C, Brozena, K M, Olthoff, S J, Schuster, S D, Nasta, E A, Stadtmauer, D E, Tsai   +10 more
openaire   +2 more sources

Donor–Recipient Epstein–Barr Virus Serostatus and Time‐Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients

Transplant Infectious Disease, EarlyView.
In a national US kidney transplant cohort, posttransplant lymphoproliferative disorder risk varied dynamically by donor–recipient Epstein–Barr virus serostatus. Donor‐positive/recipient‐negative recipients had the highest sustained risk, while donor‐negative/recipient‐negative recipients faced previously under‐recognized early risk, with PTLD strongly ...
Christie Rampersad, Seyed M. Hosseini‐Moghaddam, S. Joseph Kim   +2 more
wiley   +1 more source